signal identification and development i.ralph edwards
DESCRIPTION
Factors favouring signal detection (1) The clinical event –a very low natural frequency –characteristic or unusual signs and symptoms –occurring in groups of similar patients –known to be frequently drug-induced Drug exposure –high frequencyTRANSCRIPT
![Page 1: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/1.jpg)
Signal identificationand development
I.Ralph Edwards
![Page 2: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/2.jpg)
Adverse Reaction Signal• Reported information on a possible
causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously.
• Usually more than one report is required to generate a signal, depending on the seriousness of the event and the quality of the information.
WHO definition
![Page 3: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/3.jpg)
Factors favouring signal detection (1)
• The clinical event– a very low natural frequency– characteristic or unusual signs and
symptoms– occurring in groups of similar patients– known to be frequently drug-induced
• Drug exposure– high frequency
![Page 4: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/4.jpg)
Factors favouring signal detection (2)
• Adverse Reaction– high frequency– suggestive time relationship– suggestive dose relationship– plausible pharmacological and
pathological mechanism
![Page 5: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/5.jpg)
Speed of signal detection• depends on:
– number of users of the drug– frequency of adverse reaction– reporting rate– quality of documentation
![Page 6: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/6.jpg)
Qualitative V Quantitative signals
• Qualitative– small number of cases– suggestive time relationship– plausible mechanism
• Quantitative– relative risk calculations– more patients - better precision– comparisons within drug or between drugs
![Page 7: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/7.jpg)
Criteria for Signal Assessment
• Quantitative– strength of association
• number of case reports• statistical disproportionality
![Page 8: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/8.jpg)
• Information Component– Bayesian statistics
• Odds Ratio• Proportional ADR Reporting Ratio• Yule’s Q• Poisson• Chi square
Measures of disproportionality
![Page 9: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/9.jpg)
Disproportionality of reporting
Reports w thesuspected ADR
Reports withoutthe suspectedADR
Reports w thesuspected drug
A B
All other reports C D
![Page 10: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/10.jpg)
Criteria for Signal assessment
• Qualitative– consistency of data
• characteristic feature, pattern, absence of reverse findings
– exposure - response relationship• site, timing, dose - response relationship,
reversibility – biological plausibility
• pharmacological and pathological mechanisms
![Page 11: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/11.jpg)
Criteria for Signal Assessment (continued)– experimental findings
• rechallenge, antibodies, drug concentrations, abnormal metabolites
– analogy • previous experience with drug, often drug-
induced– nature and quality of data
• objectivity of event, validity of documentation, causality assessment
![Page 12: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/12.jpg)
Signal validation• ask reporter for more details if
missing• ask for opinion from
physician/specialist• causality assessment
![Page 13: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/13.jpg)
Signal strengthening• seek information from
– medical literature– other data bases e.g. WHO– the manufacturer– clinical trial records (if available)
• analogy with other related drugs
• Absence of supporting data does not imply false signal
![Page 14: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/14.jpg)
Seriousness• health consequences
– for individual– for public at large
• determining factor for priority setting and speed of investigation
![Page 15: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/15.jpg)
Mechanism• biological plausibility
– consult textbooks in pharmacology and medicine
– consult registration dossier• pharmacological or ideosyncratic• metabolite, degradation product,
excipient, impurity
![Page 16: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/16.jpg)
Risk Groups• interacting drugs • sex• age groups• dosage• duration of treatment• route of administration• indication
![Page 17: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/17.jpg)
Frequency determination
• estimate population at risk– data from manufacturer– sample statistics e.g. IMS– health insurance systems– drug dispensing outlets– drug importation agencies– prescription reimbursement systems– specific drug utilization studie
• determine best and worst case scenario
![Page 18: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/18.jpg)
Effectiveness/Risk Evaluation
• Risk of– no therapy at all (underlying disease)
• alternative non-drug treatments• alternative drug treatments
– has the benefit/risk situation of drug concerned changed?
![Page 19: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/19.jpg)
Effectiveness/risk Assessment
• Aspects of risk– seriousness and severity of reaction
• duration of adverse reaction• frequency of occurrence
• Aspects of benefit– seriousness of disease - likely improvement.– chronicity of disease - reduction in duration– frequency of disease - frequency of
improvement
![Page 20: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/20.jpg)
Making Decisions• do nothing, wait for more information• inform health professionals• initiate further studies
– animal studies– clinical trials– case-control– cohort
• alter product information
![Page 21: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/21.jpg)
Making Decisions (continued)
• change marketing conditions– limit indications– limit availability (specialists,
prescription, pharmacy)– suspend marketing authorization– permanently withdraw marketing
authorization• Consider likely degree of risk
reduction
![Page 22: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/22.jpg)
Information• health professionals first• press release• other authorities and WHO
![Page 23: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/23.jpg)
Follow-up• if no action is taken
– new reports coming in?• if action taken
– effects of action satisfactory ?
![Page 24: Signal identification and development I.Ralph Edwards](https://reader033.vdocuments.site/reader033/viewer/2022052706/5a4d1ae47f8b9ab05997884e/html5/thumbnails/24.jpg)
Steps from Signal to Policy
• what is a signal• case validation• signal strengthening• seriousness• mechanism• risk groups• frequency
determination• risk/benefit
evaluation
• decision• information• follow-up